Hulamin - Continued Recovery Name? Disc to BV, Well off ATH's
Hulamin (231c) - if not already held, it might be worth a further look. Small position due to liquidity/size.
Share price -93% off all-time highs.
Trading at discount to book value.
Turnaround efforts started in 2019 largely concluded.
Order books healthy.
Mkt Cap R758m vs Revenue of R8.6bn (down 20% in 2020).
Cost reductions implemented however cost reductions obscured by firmer ZAR.
Shares outstanding lower vs 5 years ago (~328m vs ~300m)
Revenue earned from SA roughly the same as that from Europe - ZAR hedge characteristics.
Con: For FY 2020, no dividend declared due to uncertain outlook.
Technical Structure: Emerging from bullish flag, rebounding off back-test of 200-day for commencement of upward trend.
Stop-loss: 189c
Share price -93% off all-time highs.
Trading at discount to book value.
Turnaround efforts started in 2019 largely concluded.
Order books healthy.
Mkt Cap R758m vs Revenue of R8.6bn (down 20% in 2020).
Cost reductions implemented however cost reductions obscured by firmer ZAR.
Shares outstanding lower vs 5 years ago (~328m vs ~300m)
Revenue earned from SA roughly the same as that from Europe - ZAR hedge characteristics.
Con: For FY 2020, no dividend declared due to uncertain outlook.
Technical Structure: Emerging from bullish flag, rebounding off back-test of 200-day for commencement of upward trend.
Stop-loss: 189c
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。